nature-biomedical-engineering

Nature Biomedical Engineering (nature-biomedical-engineering)

Journal positioning

Nature Biomedical Engineering is the Nature Portfolio journal for engineering at the

interface with biology and medicine: devices, diagnostics, therapeutics, biomaterials,

and engineered systems whose advance carries **significance for medicine or biology and

plausible translational relevance**. It selects, in the Nature style, for work that

solves a real biomedical problem with rigorous, biologically or clinically meaningful

validation — not a clever engineering demonstration with no health significance. The

defining demand is that the engineering be motivated by, and validated against, a

genuine medical or biological need; a proof-of-concept device with only benchtop data

and no biological/clinical evidence is a poor fit. This skill is a **fit /

venue-selection / re-framing** tool. It does not replace the journal's current

official author guidelines. Before submitting, re-check the live Nature Biomedical

Engineering submission guidelines on the Nature Portfolio site.

When to trigger

• The author names Nature Biomedical Engineering for a device, diagnostic, therapeutic,

or biomaterial result and wants a fit/framing and significance check.

• An engineering result must be re-framed from a benchtop demonstration into a

biomedical-significance and translational narrative with biological validation.

• The author is choosing between Nature Biomedical Engineering and biomaterials,

nature-electronics, ieee-transactions-on-biomedical-engineering, or

nature-communications.

• The author needs the journal's validation bar and its desk-reject heuristics.

Scope & topic fit

• Medical devices and engineered systems: implantable, wearable, and point-of-care

technologies validated against a clinical or biological endpoint.

• Diagnostics and biosensing: assays, imaging, and sensor platforms with demonstrated

sensitivity/specificity on biologically or clinically relevant samples.

• Therapeutics and delivery: engineered drug/gene/cell-delivery systems and

device-enabled therapies with mechanism and efficacy evidence in relevant models.

• Biomaterials and tissue engineering when the advance is engineering-driven and tied

to a biomedical function and validation, not just material characterization.

• Bioelectronics, neural interfaces, and organ-on-chip / engineered tissue systems with

measured biological performance.

• Computational and AI methods for biomedicine when validated on clinically or

biologically meaningful data with appropriate endpoints.

Method & evidence bar

• The contribution must carry an explicit biomedical-significance argument: the

unmet need, the engineered solution, and why it matters for medicine or biology.

• Validation must match the claim's level: cell/tissue, animal-model, or human/clinical

evidence with appropriate controls, endpoints, and statistics — benchtop performance

alone is insufficient for a biomedical claim.

• Performance must be benchmarked against the relevant clinical or technological state

of the art and reported under stated, comparable conditions.

• Biological and animal studies require proper experimental design (randomization,

blinding where applicable, adequate N, ethics approval) and honest reporting of

limitations.

• Translational claims must be calibrated to the evidence: clearly distinguish

proof-of-concept from validated performance, and state remaining barriers.

• Reproducibility and reporting follow Nature-Portfolio expectations, including the

reporting summary and relevant reporting guidelines for biomedical studies.

Structure & house style

• Nature-Portfolio article structure with a significance-forward abstract and

introduction; re-check current article types and length/format on the live guide.

• The introduction frames the clinical/biological problem and the engineering rationale

before technical development, in accessible language.

• Main display items are curated and load-bearing: device/assay performance with

statistics, in-vitro/in-vivo results with controls, and clear schematics of the

system and its intended use.

• Methods and extended/supplementary material carry full fabrication, assay, model, and

statistical detail; the main narrative must stand on the headline figures.

• Ethics, biosafety, and trial-registration statements must be present where applicable.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and

../../resources/official-source-map.md; start from the Nature-Portfolio anchors,

then cite the current Nature Biomedical Engineering guidelines page you checked.

• Search the live site for "Nature Biomedical Engineering submission guidelines" and

follow the current Nature-Portfolio submission system.

• Re-check article types, length/format expectations, and the abstract requirements.
• Confirm ethics approval, animal-use (e.g., ARRIVE), clinical-trial registration, and

relevant reporting-guideline requirements for biomedical studies.

• Confirm data-availability, code-availability, and reporting-summary requirements of

Nature Portfolio.

• Re-check open-access options, ORCID, competing-interests, funding,

author-contribution, and AI-use disclosure requirements.

• If the live official instructions conflict with this skill, the official instructions

win.

Pre-submission self-check

• [ ] The abstract/introduction states the unmet biomedical need and the translational significance in Nature style.
• [ ] Validation matches the claim level (cell / animal / human) with proper controls, endpoints, and statistics.
• [ ] Performance is benchmarked against the relevant clinical or technological state of the art.
• [ ] Animal/clinical studies report design (N, randomization/blinding), ethics approval, and limitations honestly.
• [ ] Translational claims are calibrated to the evidence, distinguishing proof-of-concept from validated performance.
• [ ] Data/code availability, reporting summary, and biomedical reporting guidelines are satisfied.

Common desk-reject triggers

• An engineering demonstration with no biomedical significance or no biological/clinical validation.
• Benchtop-only performance presented as a biomedical claim without in-vitro/in-vivo evidence.
• Overstated translational claims unsupported by the level of validation provided.
• Animal or clinical data with inadequate design, missing controls, or absent ethics approval.
• Performance not benchmarked against the relevant clinical or technological standard of care.
• A materials or device paper better suited to a materials or specialty engineering venue.

Re-routing decision

• Biomaterials advance centered on material design with biological evaluation → biomaterials.
• Bioelectronic/device physics advance without strong biomedical validation → nature-electronics.
• Specialty biomedical-engineering methods/instrumentation result → ieee-transactions-on-biomedical-engineering.
• Broad cross-disciplinary significance beyond biomedicine → nature-communications / science-advances.
• Mechanistic biology or therapeutic biology as the core → a dedicated biomedical/biology Nature-Portfolio venue.

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] Nature Biomedical Engineering
[Topic tags] <2–3 closest biomedical-engineering subtopics>
[Significance statement] <the unmet need + translational claim in one line>
[Validation level] benchtop / in-vitro / in-vivo / human-clinical
[Method/evidence] <does validation + benchmarking clear the biomedical significance + rigor bar?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / ethics & reporting guidelines / data & code / reporting summary / OA / disclosures>
[Re-route suggestion] <if no biomedical validation or better framed elsewhere, a matched venue>